Here's a medical Fun Fact from Michael Harris to consider before you stand under the mistletoe: http://bit.ly/hVYkMG

Genentech to fight FDA's decision to revoke breast cancer indication for Avastin.

A tiny crocheted brain? A GenePartner dating membership? These and more bio-ideas from BioWorld's Holiday Gift Guide http://bit.ly/gMIiA0

Roxanna Guilford-Blake has 12 things she wishes we knew about junk DNA, Dr. Oprah, the 12 days of Christmas and more: http://bit.ly/hDtL4e

Neurimmune deal, potentially $427M, backs Biogen's neurology promise http://bit.ly/e93wtb

EpiTherapeutics, Abbott enter epigenics oncology drug-discovery deal http://bit.ly/fMV4VK

Coming Mon in BioWorld Insight: FDA versus EMA on pirfenidone; Up-and-comers eyeing the wet AMD field; Biomarkers from live tissue

After denufosol failure, will $ISPH cash/royalties on eye drugs make it a take-out target?

"Small companies die more often from indigestion than starvation." See more at BioWorld's Best Quotes of 2010 http://bit.ly/fgSh5k

Coming in Monday’s BioWorld Insight: financing trends in 2010, what to do when placebos attack and IL-1’s potential in diabetes.

Coming Monday in BioWorld Insight: today's biotech CEO, a new player in inhaled insulin and Ariad’s chances for a ridaforolimus nod

Eisai’s Eritoran: Yet another candidate for the graveyard of sepsis failures?

BioWorld shines the light on another biotech-related nonprofit. This time, the Sanford Project: http://bit.ly/h3IDmu

Coming Monday in BioWorld Insight: opportunities in CNS disease, NPS’ survival strategy and competition heating up the DMD space.

Northera's down on Phase III futility in Parkinson's, but not out. The FDA wants to pull midodrine, and needs an alternative.

Coming Monday in BioWorld Insight: the challenges of biologics scale-up, antitrust issues that can derail M&A and the future in obesity..

Study shows that “longevity” gene protects from chronic disease – but price is high infant mortality, alcoholism rates. Always something.

Do not adjust your screen. You read it right: BioWorld Today is free for all this week #JPM14. Visit bioworld.com/jpmorgan

Coming Monday in BioWorld Insight: the tricky nature of lupus trial design, nontargeted drug resistance and challenges to CVR-based deals

Coming in Monday’s BioWorld Insight: Helix’s path to U.S. capital, the real role of compounding pharmacies and the JAK war in myelofibrosis.